Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
On February 21, 2025, Tyler Brian S., the Chief Executive Officer of McKesson Corp (NYSE:MCK), a $76 billion healthcare services giant currently trading near its 52-week high, sold 8,961 shares of the company’s common stock. The shares were sold at a price of $597.99 each, amounting to a total transaction value of approximately $5.36 million. Following this sale, Tyler retains direct ownership of 60,664 shares of McKesson stock. Additionally, he holds an indirect ownership of 215.1013 shares through the McKesson Corporation 401(k) Retirement Savings Plan. The sale was conducted under a pre-arranged trading plan, in compliance with Rule 10b5-1(c). According to InvestingPro data, McKesson maintains a "GOOD" financial health score and has delivered strong returns over the past five years. For deeper insights into insider trading patterns and 14+ additional ProTips, including exclusive Fair Value analysis, consider exploring McKesson’s comprehensive Pro Research Report.
In other recent news, McKesson Corporation reported third-quarter earnings and revenue that did not meet analyst expectations, with adjusted earnings per share of $8.03 falling short of the $8.27 consensus. Revenue for the quarter was $95.29 billion, slightly below the anticipated $95.77 billion, despite an 18% year-over-year increase. Nevertheless, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55-$32.95, with the midpoint above the analyst consensus. The company’s U.S. Pharmaceutical (TADAWUL:2070) segment experienced a 19% revenue increase, driven by higher prescription volumes and growth in the oncology platform.
Additionally, McKesson has announced plans to acquire an 80% controlling interest in PRISM Vision Holdings LLC and the Florida Cancer Specialists & Research Institute for $2.5 billion. These acquisitions are part of McKesson’s strategy to expand its specialty services. S&P Global Ratings revised McKesson’s outlook to positive, affirming its ’BBB+’ rating due to expected growth in its U.S. pharmaceutical segment and prescription technology business. Citi analyst Daniel Grosslight increased McKesson’s stock price target to $685, maintaining a Buy rating, following a quarter of mixed financial performance.
The company’s overall performance was bolstered by a 14% year-over-year growth in the U.S. Pharma’s adjusted operating profit. However, the Med-Surg division underperformed, with a 3% drop in revenue attributed to a weaker respiratory illness season. Despite these challenges, McKesson’s strategic initiatives and acquisitions are expected to support continued growth and robust cash flow generation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.